Bio-Rad Laboratories, Inc has launched a range of anti-vedolizumab antibodies to be used to support research into the treatment of ulcerative colitis (inflammatory bowel disease) and Crohn’s disease. Vedolizumab (Entyvio) is a monoclonal antibody used to treat these diseases and Bio-Rad’s anti-vedolizumab antibodies include four recombinant monoclonal anti-idiotypics that are highly specific for this humanised IgG1 kappa drug, making them highly suitable for the development of bioanalytical and patient monitoring assays.
The anti-vedolizumab antibodies are generated using Bio-Rad’s Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display, resulting in highly targeted reagents. These paratope-specific antibodies inhibit the binding of vedolizumab to its target, alpha4beta7 integrin, which makes them ideal for development of a pharmacokinetic bridging ELISA to monitor free drug levels, or as reference standards in anti-drug antibody assays. In addition, their recombinant production method ensures a consistent and secure supply.
The new antibodies are approved for in-vitro research purposes and for commercial applications for the provision of in-vitro testing services to support preclinical and clinical drug development and patient monitoring.
For further information about Bio-Rad visit www.bio-rad.com
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!